CoChat
Sign Up
Cited by 1,303

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Functional genomic landscape of acute myeloid leukaemia

Tyner, Jeffrey W., Tognon, Cristina E., Bottomly, Daniel, Wilmot, Beth, Kurtz, Stephen E., Savage, Samantha L., Long, Nicola, Schultz, Anna Reister, Traer, Elie, Abel, Melissa, Agarwal, Anupriya, Blucher, Aurora, Borate, Uma, Bryant, Jade, Burke, Russell, Carlos, Amy, Carpenter, Richie, Carroll, Joseph, Chang, Bill H., Coblentz, Cody, d’Almeida, Amanda, Cook, Rachel, Danilov, Alexey, Dao, Kim-Hien T., Degnin, Michie, Devine, Deirdre, Dibb, James, Edwards, David K., Eide, Christopher A., English, Isabel, Glover, Jason, Henson, Rachel, Ho, Hibery, Jemal, Abdusebur, Johnson, Kara, Johnson, Ryan, Junio, Brian, Kaempf, Andy, Leonard, Jessica, Lin, Chenwei, Liu, Selina Qiuying, Lo, Pierrette, Loriaux, Marc M., Luty, Samuel, Macey, Tara, MacManiman, Jason, Martinez, Jacqueline, Mori, Motomi, Nelson, Dylan, Nichols, Ceilidh, Peters, Jill, Ramsdill, Justin, Rofelty, Angela, Schuff, Robert, Searles, Robert, Segerdell, Erik, Smith, Rebecca L., Spurgeon, Stephen E., Sweeney, Tyler, Thapa, Aashis, Visser, Corinne, Wagner, Jake, Watanabe-Smith, Kevin, Werth, Kristen, Wolf, Joelle, White, Libbey, Yates, Amy, Zhang, Haijiao, Cogle, Christopher R., Collins, Robert H., Connolly, Denise C., Deininger, Michael W., Drusbosky, Leylah, Hourigan, Christopher S., Jordan, Craig T., Kropf, Patricia, Lin, Tara L., Martinez, Micaela E., Medeiros, Bruno C., Pallapati, Rachel R., Pollyea, Daniel A., Swords, Ronan T., Watts, Justin M., Weir, Scott J., Wiest, David L., Winters, Ryan M., McWeeney, Shannon K., Druker, Brian J.·2018·Nature
DOI 10.1038/s41586-018-0623-zPMC PMC6280667
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-018-0623-z

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 60

  1. Döhner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424–447 (2017). · DOI
  2. Byrd, J. C. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325–4336 (2002). · DOI
  3. Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079–1089 (2012). · DOI
  4. Lundberg, P. et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123, 2220–2228 (2014). · DOI
  5. Deininger, M. W. N., Tyner, J. W. & Solary, E. Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nat. Rev. Cancer 17, 425–440 (2017). · DOI
  6. Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179–1181 (2012). · DOI · Paper page
  7. Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478 (2014). · DOI · Paper page
  8. Huang, M. E. et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567–572 (1988). · DOI
  9. Shen, Z. X. et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89, 3354–3360 (1997). · DOI
  10. Nakao, M. et al. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 10, 1911–1918 (1996).
  11. Tse, K. F., Mukherjee, G. & Small, D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14, 1766–1776 (2000). · DOI
  12. Yamamoto, Y. et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97, 2434–2439 (2001). · DOI
  13. Yokota, S. et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11, 1605–1609 (1997). · DOI
  14. Knapper, S. et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108, 3262–3270 (2006). · DOI
  15. O’Farrell, A. M. et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 9, 5465–5476 (2003).
  16. Smith, B. D. et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669–3676 (2004). · DOI
  17. DeAngelo, D. J. et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108, 3674–3681 (2006). · DOI
  18. Stone, R. M. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377, 454–464 (2017). · DOI · Paper page
  19. Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622–626 (2013). · DOI · Paper page
  20. Rohle, D. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626–630 (2013). · DOI · Paper page
  21. Fiskus, W. et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114, 2733–2743 (2009). · DOI
  22. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53–65 (2011). · DOI
  23. Itzykson, R. et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25, 1147–1152 (2011). · DOI
  24. Welch, J. S. et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N. Engl. J. Med. 375, 2023–2036 (2016). · DOI · Paper page
  25. Konopleva, M. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6, 1106–1117 (2016). · DOI
  26. DiNardo, C. D. et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 19, 216–228 (2018). · DOI
  27. Tyner, J. W. et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 73, 285–296 (2013). · DOI
  28. Puissant, A. et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell 25, 226–242 (2014). · DOI
  29. Canisius, S., Martens, J. W. M. & Wessels, L. F. A. A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome Biol. 17, 261 (2016). · DOI
  30. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010). · DOI · Paper page
  31. Huntley, M. A. et al. ReportingTools: an automated result processing and presentation toolkit for high-throughput genomic analyses. Bioinformatics 29, 3220–3221 (2013). · DOI
  32. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013). · DOI
  33. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012). · DOI
  34. McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069–2070 (2010). · DOI
  35. Zhao, H. et al. CrossMap: a versatile tool for coordinate conversion between genome assemblies. Bioinformatics 30, 1006–1007 (2014). · DOI
  36. Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865–2871 (2009). · DOI
  37. Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013). · DOI
  38. Kottaridis, P. D. et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98, 1752–1759 (2001). · DOI
  39. Döhner, K. et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106, 3740–3746 (2005). · DOI
  40. Falini, B., Nicoletti, I., Martelli, M. F. & Mecucci, C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 109, 874–885 (2007). · DOI
  41. Huang, Q. et al. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br. J. Haematol. 142, 489–492 (2008). · DOI
  42. Wouters, B. J. et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113, 3088–3091 (2009). · DOI
  43. Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013). · DOI · Paper page
  44. Kim, D. & Salzberg, S. L. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol. 12, R72 (2011). · DOI
  45. Langfelder, P. & Horvath, S. Fast R functions for robust correlations and hierarchical clustering. J. Stat. Softw. 46, 1–17 (2012). · DOI
  46. Parsana, P. et al. Addressing confounding artifacts in reconstruction of gene co-expression networks. Preprint at https://www.biorxiv.org/content/early/2017/10/13/202903 (2017). · DOI
  47. Zheng, X. et al. A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinformatics 28, 3326–3328 (2012). · DOI
  48. Zheng, X. & Weir, B. S. Eigenanalysis of SNP data with an identity by descent interpretation. Theor. Popul. Biol. 107, 65–76 (2016). · DOI
  49. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010). · DOI
  50. Slovak, M. L., Theisen, A. & Shaffer, L. G. in The Principles of Clinical Cytogenetics (eds Gersen, S. L. & Keagle, M. B.) 23–49 (Springer, New York, 2013). · DOI
  51. Kurtz, S. E. et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc. Natl Acad. Sci. USA 114, E7554–E7563 (2017). · DOI
  52. Blucher, A. S., Choonoo, G., Kulesz-Martin, M., Wu, G. & McWeeney, S. K. Evidence-based precision oncology with the cancer targetome. Trends Pharmacol. Sci. 38, 1085–1099 (2017). · DOI
  53. Gu, Z., Eils, R. & Schlesner, M. Complex heat maps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016). · DOI
  54. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015). · DOI · Paper page
  55. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014). · DOI · Paper page
  56. Parker, H. S., Corrada Bravo, H. & Leek, J. T. Removing batch effects for prediction problems with frozen surrogate variable analysis. PeerJ 2, e561 (2014). · DOI
  57. Fraley, C. & Raftery, A. E. Enhanced model-based clustering, density estimation, and discriminant analysis software: MCLUST. J. Classif. 20, 263–286 (2003). · DOI
  58. Pison, G., Struyf, A. & Rousseeuw, P. J. Displaying a clustering with CLUSPLOT. Comput. Stat. Data Anal. 30, 381–392 (1999). · DOI
  59. Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J. Stat. Softw. 33, 1–22 (2010). · DOI · Paper page
  60. Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016). · DOI · Paper page

Cited by

See all 1,303

Metadata

Authors
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., Agarwal, A., Blucher, A., Borate, U., Bryant, J., Burke, R., Carlos, A., Carpenter, R., Carroll, J., Chang, B. H., Coblentz, C., d’Almeida, A., Cook, R., Danilov, A., Dao, K.-H. T., Degnin, M., Devine, D., Dibb, J., Edwards, D. K., Eide, C. A., English, I., Glover, J., Henson, R., Ho, H., Jemal, A., Johnson, K., Johnson, R., Junio, B., Kaempf, A., Leonard, J., Lin, C., Liu, S. Q., Lo, P., Loriaux, M. M., Luty, S., Macey, T., MacManiman, J., Martinez, J., Mori, M., Nelson, D., Nichols, C., Peters, J., Ramsdill, J., Rofelty, A., Schuff, R., Searles, R., Segerdell, E., Smith, R. L., Spurgeon, S. E., Sweeney, T., Thapa, A., Visser, C., Wagner, J., Watanabe-Smith, K., Werth, K., Wolf, J., White, L., Yates, A., Zhang, H., Cogle, C. R., Collins, R. H., Connolly, D. C., Deininger, M. W., Drusbosky, L., Hourigan, C. S., Jordan, C. T., Kropf, P., Lin, T. L., Martinez, M. E., Medeiros, B. C., Pallapati, R. R., Pollyea, D. A., Swords, R. T., Watts, J. M., Weir, S. J., Wiest, D. L., Winters, R. M., McWeeney, S. K., & Druker, B. J.
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
2018-10
Volume
562
Issue
7728
Pages
526-531
ISSN
  • 0028-0836
  • 1476-4687
DOI
10.1038/s41586-018-0623-z
PMC
PMC6280667
Cited by
1,303
References
20
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Functional genomic landscape of acute myeloid leukaemia. https://app.cochat.ai/papers/10.1038/s41586-018-0623-z
The paper
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., Agarwal, A., Blucher, A., Borate, U., Bryant, J., Burke, R., Carlos, A., Carpenter, R., Carroll, J., Chang, B. H., . . . Druker, B. J. (2018). Functional genomic landscape of acute myeloid leukaemia. Nature. https://doi.org/10.1038/s41586-018-0623-z